Definitions
Sorry, no definitions found. You may find more data at facet's.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word Facet's.
Examples
-
"We believe this transaction provides full and fair value for our stockholders and validates the potential of Facet's clinical and technology assets," said Faheem Hasnain, president and chief executive of Facet.
Abbott to Buy Facet Biotech Jay Miller 2010
-
Facet's key compounds include daclizumab, an experimental multiple-sclerosis treatment being developed with Biogen that is expected to move into late-stage development in the second quarter, and oncology compounds in early - to mid-stage development with other partners.
Abbott to Buy Facet Biotech Jay Miller 2010
-
"We believe this transaction provides full and fair value for our stockholders and validates the potential of Facet's clinical and technology assets," said Faheem Hasnain, president and chief executive of Facet.
Abbott to Buy Facet Biotech Jay Miller 2010
-
Abbott put the net transaction value at $450 million, after subtracting Facet's cash and marketable securities on hand.
Abbott to Buy Facet Biotech Jay Miller 2010
-
"We believe this transaction provides full and fair value for our stockholders and validates the potential of Facet's clinical and technology assets," said Faheem Hasnain, president and chief executive of Facet.
Abbott to Buy Facet Biotech Jay Miller 2010
-
Abbott put the net transaction value at $450 million, after subtracting Facet's cash and marketable securities on hand.
Abbott to Buy Facet Biotech Jay Miller 2010
-
Abbott put the net transaction value at $450 million, after subtracting Facet's cash and marketable securities on hand.
Abbott to Buy Facet Biotech Jay Miller 2010
-
Facet's key compounds include daclizumab, an experimental multiple-sclerosis treatment being developed with Biogen that is expected to move into late-stage development in the second quarter, and oncology compounds in early - to mid-stage development with other partners.
Abbott to Buy Facet Biotech Jay Miller 2010
-
Facet's key compounds include daclizumab, an experimental multiple-sclerosis treatment being developed with Biogen that is expected to move into late-stage development in the second quarter, and oncology compounds in early - to mid-stage development with other partners.
Abbott to Buy Facet Biotech Jay Miller 2010
-
The $380 million offer for Facet's stock and options is higher than the $365 million in cash on its balance sheet, but there's an extra bonus: Biogen would forgo a $30 million payment it currently owes Facet.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.